AbbVie Says Latest FDA Approval Expands Botox Use Beyond Face
Market Whales and Their Recent Bets on VRTX Options
Alnylam Canada Signs LOI From Pan-Canadian Pharmaceutical Alliance For The Public Reimbursement Of AMVUTTRA For The Treatment Of Hereditary Transthyretin-Mediated Amyloidosis In Adults
Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today
Vertex Coverage Resumed by UBS at Buy on Growth Potential
Market Analysis: AbbVie And Competitors In Biotechnology Industry
BMO Capital Maintains Market Perform on Neurocrine Biosciences, Lowers Price Target to $114
Neurocrine Biosciences Analyst Ratings
This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
AbbVie Is Doing 'Very Well' But Jim Cramer's Favorite? Abbott Laboratories
AbbVie Wins FDA Nod for Advanced Parkinson's Therapy
U.S. FDA Approves VYALEV For Adults Living With Advanced Parkinson's Disease
Gilead Sciences Analyst Ratings
AbbVie Analyst Ratings
Lilly, Gilead, Amgen Started at Outperform by Bernstein
Scotiabank Initiates Coverage On Vertex Pharmaceuticals With Sector Perform Rating, Announces Price Target of $480
Alnylam Pharmaceuticals Analyst Ratings
Here's How Much $100 Invested In Insmed 10 Years Ago Would Be Worth Today
$100 Invested In United Therapeutics 5 Years Ago Would Be Worth This Much Today
Vertex Pharmaceuticals Analyst Ratings